中性粒细胞驱动的炎症在儿童慢性复发性多灶性骨髓炎中的作用
该研究分析34例CRMO患者和20例对照的血样,发现患者中性粒细胞慢性活化(CD62L降低,P=0.0016)且PSTPIP2蛋白降低(P=0.0006),抗TNF治疗后二者正常化,提示中性粒细胞活化和PSTPIP2缺陷是CRMO核心特征。
要点
- CRMO患者中性粒细胞CD62L表达降低(P=0.0016),与MRI病灶负荷相关。
- PSTPIP2蛋白水平降低(P=0.0006)而mRNA升高(P=0.0005),无编码突变。
- 抗TNF治疗可使中性粒细胞活化和PSTPIP2下调恢复正常。
核心结论
- 中性粒细胞活化和炎症敏感的PSTPIP2缺陷是人类CRMO的核心特征。
- 趋化因子可能是潜在生物标志物。
- 研究机制上解释了TNF阻断为何对CRMO有临床获益。
研究设计与样本
- 研究纳入34例CRMO患者和20例对照,分析血液样本。
- 采用流式细胞术、生化检测和纯化中性粒细胞的转录组分析。
- 患者按治疗分组:未治疗或接受非甾体抗炎药、唑来膦酸或抗TNF治疗。
- 评估中性粒细胞活化、PSTPIP2表达、炎症基因反应及与临床参数的相关性。
主要发现
- CRMO中性粒细胞显示慢性活化,CD62L表达降低(P=0.0016;Mann-Whitney检验),与MRI病灶负荷相关。
- PSTPIP2蛋白水平持续降低(P=0.0006),尽管mRNA表达升高(P=0.0005)且无编码突变。
- 接受抗TNF治疗的患者中性粒细胞活化和PSTPIP2下调均正常化。
- 与小鼠模型不同,IL1B和CXCL8表达未增加。
- 转录组分析(4例患者和3例对照)显示NF-κB信号及炎症和趋化通路富集,CCL4、CCL4L2、ATL1、VNN1、H2BC7和LINC02207上调,ISL2下调。
关键数值与推荐
- CRMO中性粒细胞CD62L降低的P值为0.0016(Mann-Whitney检验)。
- PSTPIP2蛋白降低的P值为0.0006,mRNA升高的P值为0.0005。
- 转录组分析纳入4例患者和3例对照。
临床怎么用
- 中性粒细胞活化和PSTPIP2缺陷可作为CRMO的病理特征认识。
- 抗TNF治疗可纠正中性粒细胞活化和PSTPIP2下调,支持其临床使用。
- 趋化因子可能作为CRMO的潜在生物标志物用于评估疾病负担。
局限性
- 转录组分析样本量小(4例患者和3例对照)。
- 研究为横断面设计,未明确因果关系。
- PSTPIP2下调机制为推测性(炎症相关转录后调控),未直接证实。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Chronic recurrent multifocal osteomyelitis (CRMO) is a pediatric autoinflammatory bone disease with poorly defined pathophysiology and limited biomarkers. Murine models implicate neutrophils, neutrophil-derived interleukin-1β, and the adapter protein PSTPIP2, but direct evidence in human CRMO is lacking. This study aims to translate findings from mouse models to human disease by investigating the role of neutrophils and PSTPIP2 in CRMO. METHODS: Blood samples from 34 patients with CRMO and 20 controls were analyzed by flow cytometry, biochemical assays, and transcriptomic profiling of purified neutrophils. Patients were evaluated across treatment groups (untreated or treated with nonsteroidal anti-inflammatory drugs, zoledronate, or anti-tumor necrosis factor [anti-TNF] therapy). Neutrophil activation, PSTPIP2 expression, inflammatory gene responses, and correlations with clinical parameters were assessed. RESULTS: CRMO neutrophils displayed chronic activation marked by reduced CD62L expression (P = 0.0016; Mann-Whitney test), which correlated with magnetic resonance imaging lesion burden. PSTPIP2 protein levels were consistently decreased (P = 0.0006) despite elevated messenger RNA expression (P = 0.0005) and absence of coding mutations, suggesting inflammation-associated posttranscriptional regulation. Both neutrophil activation and PSTPIP2 down-regulation normalized in patients receiving anti-TNF therapy. Unlike murine models, IL1B expression and CXCL8 expression were not increased. Transcriptomic profiling (four patients and three controls) identified enrichment of NF-κB signaling and inflammatory and chemotaxis pathways with up-regulation of CCL4, CCL4L2, ATL1, VNN1, H2BC7, and LINC02207 and down-regulation of ISL2. Several transcripts correlated with clinical measures of disease burden. CONCLUSION: These findings identify neutrophil activation and inflammation-sensitive PSTPIP2 deficiency as central features of human CRMO, suggest chemokines as potential biomarkers, and mechanistically explain why TNF blockade provides clinical benefit.
引用
- Pavliuchenko N, Daněk P, Malcová H, et al. Neutrophil-Driven Inflammation in Pediatric Chronic Recurrent Multifocal Osteomyelitis. Arthritis Rheumatol. 2026. PMID: 42806909. doi:10.1002/art.70356
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。